Chemomab Therapeutics PEG Ratio

Chemomab Therapeutics (CMMB) currently reports a PEG ratio of -36.19. That is below the Healthcare sector average of 3.22. Use the charts on this page to explore Chemomab Therapeutics's PEG ratio history and peer comparisons.

Chemomab Therapeutics's PEG ratio of -36.19 is lower than the Healthcare sector average of 3.22. That is roughly 1222.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Chemomab Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -36.19, CMMB can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -36.19, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 3.22. From there, open related valuation or income-statement pages for Chemomab Therapeutics, and consider following CMMB for alerts when major investors trade the stock.

Chemomab Therapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows -36.19 versus a sector average near 3.22. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CMMB with unrelated industries.